--- title: "REF: Clinical Trial Planning, Design, Execution" slug: "ref-clinical-trial-planning-design-execution" updated: 2026-08-05T14:06:22Z published: 2026-08-05T14:06:22Z canonical: "bgtcplaybook.document360.io/ref-clinical-trial-planning-design-execution" --- > ## Documentation Index > Fetch the complete documentation index at: https://bgtcplaybook.document360.io/llms.txt > Use this file to discover all available pages before exploring further. # REF: Clinical Trial Planning, Design, Execution 1. Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry. (2015, June). Retrieved from Food and Drug Administration: [https://www.fda.gov/media/106369/download](https://www.fda.gov/media/106369/download) 2. Rare-disease researchers pioneer a unique approach to clinical trials. (2023, May 5). Retrieved from Nature Medicine: [https://www.nature.com/articles/s41591-023-02333-4](https://www.nature.com/articles/s41591-023-02333-4) ### Demonstration of direct benefit in pediatrics for sponsors in early engagements with the FDA 1. [21 CFR 50 Subpart D 50.52](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50/subpart-D/section-50.52) 2. [Human Gene Therapy for Rare Diseases, Guidance for Industry, January 2020](https://www.fda.gov/media/113807/download) 3. [Nonclinical Safety Evaluation of Pediatric Drug Products, Guidance for Industry, February 2006](https://www.fda.gov/media/119658/download) 4. [The present and future of gene therapy in pediatrics, Children’s National, May 2025](https://pediatrichealthnetwork.org/wp-content/uploads/2025/05/Future-Pediatrics-2025-PPT-GENE-THERAPY-FINAL-david-jacobsohn.pdf) 5. [Rare Pediatric Disease Designation and Priority Review Voucher Programs, September 2024](https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs) ### Bioanalytical testing 1. FDA Guidance for Industry: Bioanalytical Method Validation, May 2018 2. FDA Guidance for Industry: Human Gene Therapy for Rare Disease, January 2020 3. BGTC Bioanalytical Strategy, June 2025 4. FDA Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products, November 2013 5. FDA Guidance for Industry: Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products, August 2015 6. Chemistry, Manufacturing & Control Information for Human Gene Therapy Investigational New Drug Applications Guidance for Industry 1/2020 7. Potency Test for Cellular and Gene Therapy Products 1/2011 8. Intracellular Cytokine Staining 9. qPCR and qRT-PCR analysis ### Analysis of endpoints and statistical approach 1. U.S. Food and Drug Administration. Rare Diseases: Considerations for the Development of Drugs and Biological Products. U.S. Department of Health and Human Services, Dec. 2023, [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products) 2. U.S. Food and Drug Administration. Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products: Guidance for Industry. U.S. Department of Health and Human Services, Dec. 2020, [https://www.fda.gov/media/130897/download](https://www.fda.gov/media/130897/download) 3. U.S. Food and Drug Administration. Multiple Endpoints in Clinical Trials: Guidance for Industry. U.S. Department of Health and Human Services, Oct. 2022, [https://www.fda.gov/media/162416/download](https://www.fda.gov/media/162416/download) 4. FDA–NIH Biomarker Working Group. BEST (Biomarkers, Endpoints, and Other Tools) Resource. U.S. Food and Drug Administration and National Institutes of Health, 2016–, National Center for Biotechnology Information, [https://www.ncbi.nlm.nih.gov/books/NBK338448/](https://www.ncbi.nlm.nih.gov/books/NBK338448/) 5. U.S. Food and Drug Administration. Human Gene Therapy for Rare Diseases: Guidance for Industry. U.S. Department of Health and Human Services, Jan. 2020, [https://www.fda.gov/media/113807/download](https://www.fda.gov/media/113807/download) 6. U.S. Food and Drug Administration. Rare Diseases: Considerations for the Development of Drugs and Biological Products. U.S. Department of Health and Human Services, Dec. 2023, [Rare Diseases: Considerations for the Development of Drugs and Biological Products](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products) 7. U.S. Food and Drug Administration. Focus Area: Patient-Reported Outcomes and Other Clinical Outcome Assessments. U.S. Department of Health and Human Services, [https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-patient-reported-outcomes-and-other-clinical-outcome-assessments](https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-patient-reported-outcomes-and-other-clinical-outcome-assessments) 8. U.S. Food and Drug Administration. Use of Bayesian Methodology in the Design and Analysis of Clinical Trials for Drug and Biological Products: Draft Guidance for Industry. U.S. Department of Health and Human Services, Jan. 2026, [Use of Bayesian Methodology in the Design and Analysis of Clinical Trials for Drug and Biological Products](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products) ### Overview of clinical, medical, and data monitoring 1. [A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers: Guidance for Industry, FDA (April 2023)](https://www.fda.gov/media/121479/download) 2. [Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring: Guidance for Industry, FDA (August 2013)](https://www.fda.gov/media/116754/download) 3. [E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)](https://www.fda.gov/media/93884/download) 4. [21 CFR 312 Subpart D – Responsibilities of Sponsors and Investigators](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-D/section-312.50) 5. [ICH, Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice (E6(R2))](https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf) 6. [Long Term Follow-Up After Administration of Human Gene Therapy Products, FDA (January 2020)](https://www.fda.gov/media/113768/download) 7. [Monitoring of Clinical Trials, ICH GCP Network](https://ichgcp.net/monitoring) 8. [Use of Data Monitoring Committees in Clinical Trials, FDA (February 2024)](https://www.fda.gov/media/176107/download)